FDA Warning To Episciences: A Reassertion Of Controversial IND Guidance?
This article was originally published in The Rose Sheet
Executive Summary
In final agency guidance released Oct. 30, FDA held that clinical studies evaluating products' drug-like effects require Investigational New Drug go-ahead even if the items ultimately will be marketed as cosmetics, a position that industry argued is an unlawful reinterpretation of statutory definitions. FDA's Dec. 2 warning letter to Episciences could be read as an affirmation of the agency's shifting regulatory stance.
You may also be interested in...
National Advertising Division Shuts Down Skincarebrandsreviews Website
NourishMax agreed to discontinue “top pick” claims for its Diamond Infused Eye Cream and fold up its website that looked suspiciously to NAD like advertising in the guise of independent, honest reviews.
Cue The Class Actions! Plaintiffs React To Valisure’s Benzene Findings In Acne Drug Products
J&J, Target and Walgreens face class action complaints in California federal courts for economic harms caused by their sale of benzoyl peroxide-containing acne treatments, following Valisure’s 5 March citizen petition to the US FDA on findings of high levels of benzene in such products.
Revlon Moves To Dismiss ‘Ammonnia-Free’ Hair-Color Suit Lacking ‘Reputable Laboratory Analysis’
Ammonia is in fact absent from “Ammonia-Free” Creme of Nature Moisture-Rich Hair Color with Shea Butter Conditioner, and what’s missing from plaintiff’s class action complaint is lab testing to corroborate her findings at home using ill-suited testing strips, Revlon says.